T Cell Lymphomas
From the Journals
The risks of Hodgkin, non-Hodgkin, and cutaneous T-cell lymphoma were more common among males than females.
LA JOLLA, CALIF. – Researchers found the risk of second malignancy was highest among MF patients aged 30 to 50 years and patients who had tumor...
The latest update from the Food and Drug Administration includes medical device reports between September 2017 and September 2018.
LA JOLLA, CALIF. – A small number of patients experienced disease stabilization or regression on cobomarsen.
LA JOLLA, CALIF. – Some CTCL patients experienced relief from itching after just one pill.
LA JOLLA, CALIF. – Researchers plan to expand the duvelisib plus romidepsin arm to better understand the occurrence of transaminitis and assess...
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
The designation is based on results from a phase 1 trial of 35 patients.
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.